Professional Documents
Culture Documents
Hepatitis B
Barbara A. Haber, Joan M. Block, Maureen M. Jonas, Saul J. Karpen, W. Thomas
London, Brian J. McMahon, Karen F. Murray, Michael R. Narkewicz, Philip
Rosenthal and Kathleen B. Schwarz
Pediatrics published online Oct 5, 2009;
DOI: 10.1542/peds.2009-0567
The online version of this article, along with updated information and services, is
located on the World Wide Web at:
http://www.pediatrics.org
e2 HABER et al
Downloaded from www.pediatrics.org. Provided by Indonesia:AAP Sponsored on October 5, 2009
SPECIAL ARTICLES
fection are not treated. During the going into an inactive HBsAg-carrier ment at early time points, and lifetime
immune-active phase, serum viral DNA phase. It is important to recognize this monitoring are essential for success-
levels decline, there is elevation of the phase of infection, because the viral ful management of chronic HBV infec-
ALT level, and inflammation and fibro- variant is more virulent and may re- tion in children.
sis can develop in the liver. HBsAg and quire antiviral therapy to prevent liver
HBeAg remain detectable in serum. damage from occurring over time. SCREENING AND REFERRAL
Most children are still without signs or Recent findings regarding the patho- The panel collectively endorses the up-
symptoms of disease, yet the longer a physiology of HBV liver infection are dated (2008) Centers for Disease Con-
person remains in the immune-active particularly noteworthy for the practi- trol and Prevention (CDC) guidelines
phase, the more likely he or she will tioner. In a study of Asian subjects, for HBV testing and recommendations
develop chronic liver damage, cirrho- 20% to 25% of individuals with chronic for evaluation and management for
sis, and HCC. Most children will eventu- chronically infected people.11 A notable
hepatitis B developed severe hepatic
ally have undetectable HBeAg and de- change in the recent update is the rec-
fibrosis before the age of 25 years.19
velop antibody to the HBeAg (anti-HBe) ommendation to screen all individuals
These individuals most likely acquired
during childhood or early adulthood, born in geographic regions with an
their disease in childhood and may
except for those children infected with HBsAg prevalence of ⱖ2%, revised
have experienced a prolonged period
HBV genotype C, the genotype com- from ⱖ8% in the earlier guidelines.
in the immune-active phase. The Risk
monly found in Asia. There is increas-
Evaluation of Viral Load Elevation and This CDC update aimed to improve
ing evidence that what was previously
Associated Liver Disease/Cancer- identification of immigrants who ac-
attributed to ethnic differences is
Hepatitis B Virus (REVEAL-HBV) study quired HBV in their country of origin.
most likely influenced by genotype. A
suggested that during the immune- Previously, international adoptees
recent study by Livingston et al17 of a
active phase, high HBV DNA levels and were commonly screened for HBV, but
cohort of 1158 people found that the
elevated ALT levels are associated with children who immigrated with their in-
mean age of HBeAg clearance was 47.8
greater risk of cirrhosis and HCC.20–22 tact families were not. The CDC also
years for genotype C, whereas for ge-
In this study of adults whose average recommends that children born in the
notypes A, B, D, and F, the mean age of
age was mid-40s, serum ALT levels as United States to immigrant parents
HBeAg clearance occurred before 20
low as twice the upper limit of normal from endemic areas be screened, and
years. Furthermore, genotype C is
(ULN) were associated with progres- all children born to HBsAg-positive
more likely to revert to an HBeAg-
sion to cirrhosis and HCC. These find- mothers should be tested (generally at
positive state and more likely to be
ings have prompted a new, more ag- 1 year of age). In addition, children
transmitted vertically. When HBeAg be-
gressive approach to the treatment who live in a household with a known
comes undetectable and anti-HBe is
of adults during the immune-active HBsAg-positive person(s) should be
present, most persons move into the
phase of chronic hepatitis B. The new screened. Even those who received
inactive HBsAg-carrier phase, in which
guidelines for chronically infected vaccine but were not ever tested for
the viral DNA level is low (usually
⬍2000 IU/mL [10 000 copies per mL]) adults have led to a heightened aware- HBV infection should be tested in case
or undetectable, the ALT level normal- ness among pediatric liver specialists they were infected before vaccination
izes, liver histology is without inflam- that treatment during a prolonged or did not develop an adequate re-
mation, hepatic fibrosis may regress, immune-active phase is important for sponse to the vaccination (Table 1).
and the risk of cirrhosis and HCC de- decreasing an infected child’s risk of Serum HBsAg, along with anti-HBs, is
clines. Another phase is the reactiva- developing cirrhosis and/or cancer the most effective screening tool for
tion phase, which occurs in 20% to 30% later in life. In addition, a strict linkage HBV infection. HBsAg is detectable in
of patients.18 In this phase, viral DNA of ALT level with progression of liver virtually all individuals with chronic in-
levels increase, whereas HBeAg re- disease is not always apparent, espe- fection, even when HBV DNA levels are
mains undetectable. The ALT level cially in children.23 Practitioners need undetectable. A lack of anti-HBs identi-
may be either normal or elevated. This to rigorously monitor HBV-infected pa- fies susceptible children who need
is also termed e-antigen–negative tients at regular intervals (every 6 to vaccination. Children found to be
chronic hepatitis B and is usually 12 months) and refer to a pediatric HBsAg-positive should be retested 6
caused by infection with a mutant vi- liver specialist any patient who has el- months later to document chronic in-
rus. In addition, some persons may evated ALT and HBV DNA levels. Vacci- fection. As noted above, serum ALT lev-
move directly into this phase without nation, screening, referral for treat- els are not elevated in children in the
e4 HABER et al
Downloaded from www.pediatrics.org. Provided by Indonesia:AAP Sponsored on October 5, 2009
SPECIAL ARTICLES
age. In the absence of guidelines for levels of children with detectable in the immune-active phase and being
children, the panel recommends that HBeAg and normal ALT levels. During considered for treatment and for
the ALT level be considered elevated if the immune-tolerant phase, when the those in the inactive HBsAg-carrier
it is greater than the testing laboratory child is not a candidate for treatment, phase to detect reactivation.
ULN or ⬎40 IU/L, whichever is lower. DNA levels may exceed 20 000 IU/mL The panel did not reach a consensus
Children with a family history that and are thought to have little predic- regarding the frequency of ultrasound
is suspicious for hepatitis B–related tive value regarding the risk of cancer after a baseline examination. For the
cirrhosis or liver cancer should be or cirrhosis. Likewise, children in the majority of infants and toddlers, can-
considered to be at high risk, and a inactive HBsAg-carrier phase (anti- cer and cirrhosis are unlikely events.
pediatric liver specialist should be HBe–positive and normal ALT level) do Even for young school-aged children
consulted concerning the frequency of not need monitoring of HBV DNA levels
the risk is minimal. Given the infre-
appropriate monitoring, taking into unless the ALT level becomes elevated,
quency of these events before young
consideration the age of the patient which may signify reactivation of HBV.
adulthood, there is no evidence-based
and the specifics of the family history. However, children in the inactive
guidance for ultrasound monitoring.
AFP is a marker of risk of HCC, but for HBsAg-carrier phase do need to have
For adolescents, many pediatric liver
children as well as adults, an elevated their ALT levels monitored every 6 to 12
specialists adopt the same guide-
AFP level alone often does not indicate months for the rest of their lives, and if
lines used by adult hepatologists and
whether HCC is present. AFP elevations the ALT level rises above normal, then
perform ultrasound every 6 months
commonly occur with active liver in- the HBV DNA level should be assessed.
for those with cirrhosis or an ele-
flammation and during pregnancy. It is important to remember that, as a
vated AFP level and/or a family his-
Therefore, the AFP level is best used result of the obesity epidemic in chil-
tory of HCC.
to stratify risk categories. In a dren, elevated ALT levels may be re-
lated to nonalcoholic fatty liver dis- In summary, adult treatment guide-
population-based study of children
ease (NAFLD), an increasingly common lines are rapidly evolving as an in-
and adults, AFP level was useful in
identifying most children who devel- finding in children with metabolic creasing range of therapies become
oped HCC at a treatable stage, and a syndrome. Thus, some children with available, as multidrug regimens are
normal AFP level had a high negative HBV infection in the inactive HBsAg- studied, and as interest in developing
predictive value for HCC.25 In the ab- carrier phase may have elevated ALT treatments for individuals with normal
sence of pediatric-specific studies on levels resulting from NAFLD or other ALT levels grows. At this time, however,
the usefulness of AFP levels, the panel causes, but as expected in this many of these newer therapies and
endorses periodic AFP testing. Increas- phase, the HBV DNA level will not be strategies have not been adequately
ing serum AFP levels correspond to in- elevated above 2000 IU/mL (10 000 evaluated in children. The panel rec-
creasing HCC risk, and an AFP level of copies per mL). ommends that any child with an ele-
⬎10 ng/mL merits ultrasound evalua- During the immune-active phase, the vated ALT and/or AFP level and/or a
tion for nodules and referral to a pedi- HBV DNA level can be helpful in design- positive family history for liver dis-
atric liver specialist for further evalu- ing a treatment plan (eg, HBV DNA lev- ease, especially liver cancer, be re-
ation and guidance. Although HCC els may predict the likelihood of re- ferred to a pediatric liver specialist
associated with HBV is a rare event in sponse to some treatment regimens, who will advise on opportunities to
childhood, it is important to remem- but it might only be measured if treat- treat and/or the need for further eval-
ber that some children develop HCC ment is being considered). During the uation. The specialist will also recom-
without cirrhosis and can do so be- inactive HBsAg-carrier phase, DNA lev- mend a strategy for long-term moni-
fore reaching adulthood.26,27 Further- els are undetectable, and it is during toring. In more urban areas, a local
more, children with documented cir- this phase that monitoring DNA levels pediatric liver specialist often as-
rhosis, a family history of HCC, and can be useful to identify reactivation; sumes responsibility for monitoring,
an elevated AFP level should be reg- thus, HBV DNA may be measured annu- whereas in more rural areas in which
ularly screened for HCC at 6-month ally. The panel concluded that there a specialist may not be geographically
intervals with liver ultrasound and was little value in routine monitoring accessible, it may be primary care
AFP-level measurement. of HBV DNA levels for those children practitioners who continue to monitor
In general, the panel did not recom- with normal ALT levels, but routine and treat in consultation with the
mend routine monitoring of HBV DNA monitoring is useful for those who are specialist.
e6 HABER et al
Downloaded from www.pediatrics.org. Provided by Indonesia:AAP Sponsored on October 5, 2009
SPECIAL ARTICLES
9. Centers for Disease Control and Prevention. 16. Dayan GH, Caquías CR, García Y, et al. Medical B: a 16-year population-based study. Hepatol-
Screening for chronic hepatitis B among practices for prevention of perinatal infec- ogy. 2000;32(4 pt 1):842– 846
Asian/Pacific Islander populations: New York tions in Puerto Rico. Paediatr Perinat Epide- 26. Heyward WL, Lanier AP, McMahon BJ, Fitzger-
City, 2005. MMWR Morb Mortal Wkly Rep. 2006; miol. 2008;22(1):31–39 ald MA, Kilkenny S, Paprocki TR. Early detec-
55(18):505–509 17. Livingston SE, Simonetti JP, Bulkow LR, et al. tion of primary hepatocellular carcinoma:
10. Mast EE, Margolis HS, Fiore AE, et al. A compre- Clearance of hepatitis B e antigen in patients screening for primary hepatocellular carci-
hensive immunization strategy to eliminate with chronic hepatitis B and genotypes A, B, C, noma among persons infected with hepatitis
transmission of hepatitis B virus infection in D, and F. Gastroenterology. 2007;133(5): B virus. JAMA. 1985;254(21):3052–3054
the United States: recommendations of the Ad- 1452–1457 27. Livingston SE, Simonetti JP, McMahon BJ, et al.
visory Committee on Immunization Practices 18. Hsu YS, Chien RN, Yeh CT, et al. Long-term out- Hepatitis B virus genotypes in Alaska Native
(ACIP) part 1—immunization of infants, chil- come after spontaneous HBeAg seroconver- people with hepatocellular carcinoma: pre-
dren, and adolescents [published corrections sion in patients with chronic hepatitis B. Hepa- ponderance of genotype F. J Infect Dis. 2007;
appear in MMWR Morb Mortal Wkly Rep. 2006; tology. 2002;35(6):1522–1527 195(1):5–11
55(6):158 –159; and MMWR Morb Mortal Wkly 19. Fung J, Lai CL, But D, Wong D, Cheung TK, Yuen 28. Sokal EM, Kelly DA, Mizerski J, et al. Long-term
Rep. 2007;56(48):1267]. MMWR Recomm Rep. MF. Prevalence of fibrosis and cirrhosis in lamivudine therapy for children with HBeAg-
2005;54(RR-16):1–31 chronic hepatitis B: implications for treatment positive chronic hepatitis B. Hepatology. 2006;
11. Weinbaum CM, Williams I, Mast EE, et al; Cen- and management. Am J Gastroenterol. 2008; 43(2):225–232
ters for Disease Control and Prevention. Rec- 103(6):1421–1426 29. Pallier C, Rodriguez C, Brillet R, Nordmann P,
ommendations for identification and public 20. Chen CJ, Iloeje UH, Yang HI. Long-term out- Hézode C, Pawlotsky JM. Complex dynamics of
health management of persons with comes in hepatitis B: the REVEAL-HBV study. hepatitis B virus resistance to adefovir. Hepa-
chronic hepatitis B virus infection. MMWR Clin Liver Dis. 2007;11(4):797– 816 tology. 2009;49(1):50 –59
Recomm Rep. 2008;57(RR-8):1–20. Available at: 21. Chen CJ, Yang HI, Su J, et al. Risk of hepatocel- 30. Burczynska B, Madalinski K, Pawlowska J,
www.cdc.gov/mmwr/preview/mmwrhtml/ lular carcinoma across a biological gradient et al. The value of quantitative measure-
rr5708a1.htm. Accessed February 23, 2009 of serum hepatitis B virus DNA level. JAMA. ment of HBeAg and HBsAg before
12. Chang MH, Chen CJ, Lai MS, et al. Universal 2006;295(1):65–73 interferon-alpha treatment of chronic
hepatitis B vaccination in Taiwan and the inci- 22. Lai CL, Yuen MF. The natural history and treat- hepatitis B in children. J Hepatol. 1994;
dence of hepatocellular carcinoma in chil- ment of chronic hepatitis B: a critical evalua- 21(6):1097–1102
dren. N Engl J Med. 1997;336(26):1855–1859 tion of standard treatment criteria and end 31. Kobak GE, MacKenzie T, Sokol RJ, Narkewicz
13. Chang MH, Chen TH, Hsu HM, et al. Prevention points. Ann Intern Med. 2007;147(1):58 – 61 MR. Interferon treatment for chronic hepatitis
of hepatocellular carcinoma by universal vac- 23. Wang CC, Lim LY, Deubner H, et al. Factors pre- B: enhanced response in children 5 years old
cination against hepatitis B virus: the effect dictive of significant hepatic fibrosis in adults or younger. J Pediatr. 2004;145(3):340 –345
and problems. Clin Cancer Res. 2005;11(21): with chronic hepatitis B and normal serum 32. Keeffe EB, Dieterich DT, Han SH, et al. A
7953–7957 ALT. J Clin Gastroenterol. 2008;42(7):820 – 826 treatment algorithm for the management
14. Zuckerman JN. Review: hepatitis B immune 24. Prati D, Taioli E, Zanella A, et al. Updated defini- of chronic hepatitis B virus infection in
globulin for prevention of hepatitis B infection. tions of healthy ranges for serum alanine ami- the United States: 2008 update. Clin Gas-
J Med Virol. 2007;79(7):919 –921 notransferase levels. Ann Intern Med. 2002; troenterol Hepatol. 2008;6:1315–1341;
15. Shepard CW, Finelli L, Fiore AE, Bell BP. Epide- 137(1):1–10 quiz 1286
miology of hepatitis B and hepatitis B virus 25. McMahon BJ, Bulkow L, Harpster A, et al. 33. Lok AS, McMahon BJ. Chronic hepatitis B [pub-
infection in United States children. Pediatr In- Screening for hepatocellular carcinoma in lished correction appears in Hepatology. 2007;
fect Dis J. 2005;24(9):755–760 Alaska natives infected with chronic hepatitis 45(6):1347]. Hepatology. 2007;45(2):507–539